Two Sigma Advisers
YMAB

Two Sigma Advisers’s Y-mAbs Therapeutics YMAB Stock Holding History

Two Sigma Advisers’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-115,700
Closed -$522K – 2674
2025
Q2 		$522K Sell
115,700
-27,600
-19% -$124K ﹤0.01% 1730
2025
Q1 		$635K Buy
143,300
+69,400
+94% +$403K ﹤0.01% 1676
2024
Q4 		$579K Sell
73,900
-11,100
-13% -$135K ﹤0.01% 1728
2024
Q3 		$1.12M Sell
85,000
-12,700
-13% -$161K ﹤0.01% 1365
2024
Q2 		$1.18M Sell
97,700
-32,700
-25% -$441K ﹤0.01% 1469
2024
Q1 		$2.12M Sell
130,400
-34,600
-21% -$466K ﹤0.01% 1192
2023
Q4 		$1.13M Sell
165,000
-37,200
-18% -$215K ﹤0.01% 1587
2023
Q3 		$1.1M Sell
202,200
-8,000
-4% -$46.6K ﹤0.01% 1479
2023
Q2 		$1.43M Buy
210,200
+1,000
+0.5% +$7.49K ﹤0.01% 1376
2023
Q1 		$1.05M Buy
209,200
+143,100
+216% +$584K ﹤0.01% 1606
2022
Q4 		$323K Buy
+66,100
New +$480K ﹤0.01% 2041
2022
Q2 		– Sell
-11,100
Closed -$132K – 2906
2022
Q1 		$132K Sell
11,100
-13,300
-55% -$137K ﹤0.01% 2456
2021
Q4 		$396K Sell
24,400
-24,600
-50% -$526K ﹤0.01% 2028
2021
Q3 		$1.4M Sell
49,000
-86,300
-64% -$2.72M ﹤0.01% 1452
2021
Q2 		$4.57M Sell
135,300
-104,800
-44% -$3.36M 0.01% 905
2021
Q1 		$7.26M Buy
240,100
+126,900
+112% +$5.2M 0.02% 698
2020
Q4 		$5.61M Buy
113,200
+12,300
+12% +$569K 0.02% 777
2020
Q3 		$3.87M Buy
100,900
+21,600
+27% +$860K 0.01% 859
2020
Q2 		$3.43M Buy
79,300
+14,900
+23% +$563K 0.01% 956
2020
Q1 		$1.68M Buy
64,400
+21,100
+49% +$613K 0.01% 1205
2019
Q4 		$1.35M Buy
+43,300
New +$1.28M ﹤0.01% 1417

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Two Sigma Advisers's YMAB Position: Q3 2025 in Review

Two Sigma Advisers sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 115,700 shares — an estimated $522K sold.

Two Sigma Advisers first reported a position in YMAB in Q4 2019 and held it in 21 quarters. The position peaked at $7.26M in Q1 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Two Sigma Advisers reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 115,700 Y-mAbs Therapeutics shares in Q3 2025, an estimated $522K.
  • Two Sigma Advisers first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 21 quarters.
  • Two Sigma Advisers's Y-mAbs Therapeutics position peaked at $7.26M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.